High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

NCT01534143 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Data was not collected, because funding was unavailable to continue study.

Conditions

Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions

OTHER: pharmacological study
DRUG: tacrolimus
DRUG: sirolimus
BIOLOGICAL: anti-thymocyte globulin
DRUG: fludarabine phosphate
DRUG: busulfan
DRUG: bortezomib
PROCEDURE: allogeneic hematopoietic stem cell transplantation
OTHER: laboratory biomarker analysis

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]